ATE288268T1 - Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden - Google Patents

Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden

Info

Publication number
ATE288268T1
ATE288268T1 AT99960663T AT99960663T ATE288268T1 AT E288268 T1 ATE288268 T1 AT E288268T1 AT 99960663 T AT99960663 T AT 99960663T AT 99960663 T AT99960663 T AT 99960663T AT E288268 T1 ATE288268 T1 AT E288268T1
Authority
AT
Austria
Prior art keywords
glp
receptor
peptide
antagonists
methods
Prior art date
Application number
AT99960663T
Other languages
English (en)
Inventor
Larry Kenneth Truesdale
Richard A Bychowski
Javier Gonzalez
Atsuo Kuki
Ranjan Jagath Rajapakse
Min Teng
Dan Kiel
Daljit S Dhanoa
Yufeng Hong
Tso-Sheng Chou
Anthony L Ling
Michael David Johnson
Vlad Edward Gregor
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of ATE288268T1 publication Critical patent/ATE288268T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
AT99960663T 1998-12-10 1999-12-08 Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden ATE288268T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11173698P 1998-12-10 1998-12-10
PCT/US1999/029065 WO2000033839A1 (en) 1998-12-10 1999-12-08 Non-peptide antagonists of glp-1 receptor and methods of use

Publications (1)

Publication Number Publication Date
ATE288268T1 true ATE288268T1 (de) 2005-02-15

Family

ID=22340176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960663T ATE288268T1 (de) 1998-12-10 1999-12-08 Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden

Country Status (14)

Country Link
US (1) US6469021B1 (de)
EP (1) EP1137413B1 (de)
JP (1) JP2002531501A (de)
KR (1) KR20010089563A (de)
AT (1) ATE288268T1 (de)
AU (1) AU758968B2 (de)
BR (1) BR9916965A (de)
CA (1) CA2350887A1 (de)
DE (1) DE69923587T2 (de)
ES (1) ES2233089T3 (de)
NZ (1) NZ511698A (de)
PT (1) PT1137413E (de)
WO (1) WO2000033839A1 (de)
ZA (1) ZA200104128B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085256A2 (en) 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
AU2002221222A1 (en) * 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
AU2003203146A1 (en) * 2002-02-07 2003-09-02 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
CA2474460C (en) * 2002-02-13 2009-12-22 F. Hoffmann-La Roche Ag Pyridine- and quinoline-derivatives
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
WO2008085982A2 (en) 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
CA2700160A1 (en) * 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
WO2009067233A1 (en) * 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
EP3978011A1 (de) 2015-05-22 2022-04-06 The Board of Trustees of the Leland Stanford Junior University Behandlung von post-bariatrischer hypoglykämie mit glp-1-antagonisten
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
CN111362937B (zh) * 2020-03-06 2021-06-22 贵州医科大学 N-芳基-β-卡波林类衍生物及其用途
BR112022026385A2 (pt) * 2020-07-23 2023-01-31 Merck Patent Gmbh Heterociclos tricíclicos
US20230390250A1 (en) * 2020-10-30 2023-12-07 Robin Elaine DUNCAN Modulation of glucagon-like peptide 1 and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834482A (en) * 1995-05-05 1998-11-10 Novo Nordisk A/S Heterocyclic chemistry

Also Published As

Publication number Publication date
AU1751800A (en) 2000-06-26
KR20010089563A (ko) 2001-10-06
PT1137413E (pt) 2005-05-31
DE69923587D1 (de) 2005-03-10
US6469021B1 (en) 2002-10-22
NZ511698A (en) 2003-09-26
ES2233089T3 (es) 2005-06-01
DE69923587T2 (de) 2005-06-23
EP1137413A2 (de) 2001-10-04
WO2000033839A1 (en) 2000-06-15
CA2350887A1 (en) 2000-06-15
EP1137413B1 (de) 2005-02-02
JP2002531501A (ja) 2002-09-24
WO2000033839B1 (en) 2000-09-28
BR9916965A (pt) 2001-11-06
EP1137413A4 (de) 2002-06-26
AU758968B2 (en) 2003-04-03
ZA200104128B (en) 2002-05-21

Similar Documents

Publication Publication Date Title
ATE288268T1 (de) Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
EP1590336A4 (de) Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
MX9500072A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
EP1773330A4 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
YU22000A (sh) Biciklični inhibitori kinaze
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
ES2154167B1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
ES2000299A6 (es) Procedimiento para la preparaciom de nuevos derivados de n-aralquil-piperinmetanol
IL139956A0 (en) Conformationally constrained backbone cyclized somatostatin analogs
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
EP1181555A4 (de) Krebsbehandlung mit antagonisten des endothelinrezeptors
GR950300029T1 (en) Dna encoding a human serotonin receptor (5-ht4b)a nd uses thereof.
MY127385A (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperlasia
HK1064683A1 (en) Receptor of the edb fibronectin domains (II)
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
EP0960937A4 (de) Neues semaphorin-gen: semaphorin y
ATE514778T1 (de) G-protein-gekoppelte rezeptor-antagonisten
GB0011071D0 (en) Organic compounds
NZ513053A (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
EP1346983A3 (de) Phthalimido-arylpiperazine als alpha 1A Rezeptor Antagonisten nützlich zur Behandlung von gutartiger Prostatahyperplasie
DK1235850T3 (da) Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137413

Country of ref document: EP

REN Ceased due to non-payment of the annual fee